Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Sales & Earnings Business Strategies Commercial

Lundbeck Ready To Funnel 2022 Growth Into Expected Alzheimer’s Agitation Launch

  • Analysis

Executive Summary

The Danish firm’s four key products yielded 31% sales growth in 2022, and the company is investing in the anticipated mid-year launch of an Alzheimer’s agitation indication for Rexulti.

You may also be interested in...



Lundbeck And Axsome Rival Candidate Data Raise Prospects For First Alzheimer’s Agitation Approvals

The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.

Lundbeck Ready To File Alzheimer’s Agitation Treatment, A Potential First

Brexpiprazole could be approved as soon as 2023, and Lundbeck has pledged to support its uptake with investment in its salesforce and direct-to-consumer advertising.

Lundbeck/Otsuka Global Alliance Will Support Lundbeck's Move Into U.S. Psychiatry Market

Table

View full table

Topics

Related Companies

Tags:
Sales & Earnings Business Strategies Commercial
Latest Headlines

First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands

ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Roche Continues To Cast Its Collaborations Net Wide

See All
UsernamePublicRestriction

Register

SC147880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By